Trial Profile
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Astex Pharmaceuticals; Otsuka Pharmaceutical
- 21 Jan 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Early termination not due to patient safety
- 17 Nov 2021 This trial has been completed in Austria (end date: 4 Oct 2021), according to European Clinical Trials Database record.
- 05 Nov 2021 This trial has been completed in Hungary (Global end date: 4 Oct 2021).